Open to Debate: Is the FDA too Cautious?


During the COVID-19 pandemic, the Atlantic lambasted the US Food and Drug Administration for moving too slowly to approve vaccines with the provocative headline “The Death Toll of Delay.” Not long before, National Public Radio had run a piece titled “One-Third of New Drugs Had Safety Problems After FDA Approval.” As the agency tries to move safe and effective drugs as quickly as possible to patients who need them, it also needs to maintain the diligence and rigor necessary to prevent harms. Two experts look at the pace of FDA approvals and argue whether the agency is getting it right.

  • 2023 Health

Explore More


252 ideas
Sorry, we couldn't find any results
Clear filters

Thank you for signing up!

Please provide a valid email address.

Please provide a valid email address.
Sign up to receive the latest
updates from Aspen Ideas.